Updated publication reference for PubMed record(s): 34244494. We investigated the functions of ECM1 subtypes ECM1a (inlcuding wild type and mutant) and ECM1b in ovarian cancer cell line HEYA8. While ECM1a is oncogenic, ECM1b is a tumor suppressor. To identify the molecules binding to ECM1a or ECM1b within cells, protein samples were generated by co-IP using HA antibody to pull down proteins potentially binding to ECM1a (HA-tagged) (samples: P20170700270A1/A2/A3/A4) or ECM1b (HA-tagged) (samples: P20170700270B1/B2/B3/B4) within cells indicated in gel image P20170700270. To identify more cell surface markers besides integrins alpha X and beta 2 binding to ECM1a-WT or ECM1a-MT, three batches of protein samples were generated by co-IP using HA antibody to pull down total proteins binding to ECM1a-WT or ECM1a-MT shown in gel image R20191201880, or to pull down membrane fractionation proteins binding to ECM1a-WT or ECM1a-MT indicated in gel image 20200100053, or to pull down membrane fractionation proteins of HEYA8 cells treated with ECM1a-WT or ECM1a-MT conditioned media binding to ECM1-WT or ECM1a-MT shown in gel image 20200100054.